Yunping Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yunping Hu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Wesley Hsu
Department of Neurological Surgery, Wake Forest University School of Medicine, Winston-Salem, NC, USA
3 shared publications Fei Xing
Department of Cancer Biology, Medical Center Boulevard, Wake Forest University School of Medicine, Winston- Salem, USA
2 shared publicationsAkiva Mintz
Department of Radiology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA
1 shared publicationBaisong Lu
Medical Center Boulevard, Wake Forest University Institute for Regenerative Medicine, Winston-Salem, USA
1 shared publicationW. Jeffrey Petty
Department of Hematology and Oncology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA
1 shared publicationXin Feng
Department of Otolaryngology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA
1 shared publication
Latest Publications
- Open Access
- 18 May 2023
- Published by Springer Nature in Discover Oncology
- Vol. 14 (1) , 1-12
Virus-like particle-based delivery of Cas9/guide RNA ribonucleoprotein efficiently edits the brachyury gene and inhibits chordoma growth in vivo
Purpose: Chordoma is a rare and aggressive bone cancer driven by the developmental transcription factor brachyury. Efforts to target brachyury are hampered by the absence of ligand-accessible small-molecule binding pockets. Genome editing with CRISPR systems provides an unprecedented opportunity to modulate undruggable transcription factor targets. However, delivery of CRISPR remains a bottleneck for in vivo therapy development. The aim was to investigate the in vivo therapeutic efficiency of Cas9/guide RNA (gRNA) ribonucleoprotein (RNP) delivery through a novel virus-like particle (VLP) by fusing an aptamer-binding protein to the lentiviral nucleocapsid protein.Methods: The p24 based ELISA and transmission electron microscopy were used to determine the characterization of engineered VLP-packaged Cas9/gRNA RNP. The deletion efficiency of brachyury gene in chordoma cells and tissues was measured by genome cleavage detection assay. RT-PCR, Western blot, immunofluorescence staining, and IHC were employed to test the function of brachyury deletion. Cell growth and tumor volume were measured to evaluate the therapeutic efficiency of brachyury deletion by VLP-packaged Cas9/gRNA RNP.Results: Our “all-in-one” VLP-based Cas9/gRNA RNP system allows for transient expression of Cas9 in chordoma cells, but maintains efficient editing capacity leading to approximately 85% knockdown of brachyury with subsequent inhibition of chordoma cell proliferation and tumor progression. In addition, this VLP-packaged brachyury-targeting Cas9 RNP avoids systemic toxicities in vivo.Conclusion: Our preclinical studies demonstrate the potential of VLP-based Cas9/gRNA RNP gene therapy for the treatment of brachyury-dependent chordoma.
- 18 May 2023
- Published by Springer Nature in Discover Oncology
- Vol. 14 (1) , 1-12
Open AccessVirus-like particle-based delivery of Cas9/guide RNA ribonucleoprotein efficiently edits the brachyury gene and inhibits chordoma growth in vivo
Purpose: Chordoma is a rare and aggressive bone cancer driven by the developmental transcription factor brachyury. Efforts to target brachyury are hampered by the absence of ligand-accessible small-molecule binding pockets. Genome editing with CRISPR systems provides an unprecedented opportunity to modulate undruggable transcription factor targets. However, delivery of CRISPR remains a bottleneck for in vivo therapy development. The aim was to investigate the in vivo therapeutic efficiency of Cas9/guide RNA (gRNA) ribonucleoprotein (RNP) delivery through a novel virus-like particle (VLP) by fusing an aptamer-binding protein to the lentiviral nucleocapsid protein.Methods: The p24 based ELISA and transmission electron microscopy were used to determine the characterization of engineered VLP-packaged Cas9/gRNA RNP. The deletion efficiency of brachyury gene in chordoma cells and tissues was measured by genome cleavage detection assay. RT-PCR, Western blot, immunofluorescence staining, and IHC were employed to test the function of brachyury deletion. Cell growth and tumor volume were measured to evaluate the therapeutic efficiency of brachyury deletion by VLP-packaged Cas9/gRNA RNP.Results: Our “all-in-one” VLP-based Cas9/gRNA RNP system allows for transient expression of Cas9 in chordoma cells, but maintains efficient editing capacity leading to approximately 85% knockdown of brachyury with subsequent inhibition of chordoma cell proliferation and tumor progression. In addition, this VLP-packaged brachyury-targeting Cas9 RNP avoids systemic toxicities in vivo.Conclusion: Our preclinical studies demonstrate the potential of VLP-based Cas9/gRNA RNP gene therapy for the treatment of brachyury-dependent chordoma.
- 17 August 2022
- Published by Elsevier in Cancer Letters
- Vol. 547, 215867
FGFR1/MAPK-directed brachyury activation drives PD-L1-mediated immune evasion to promote lung cancer progression
- 17 August 2022
- Published by Elsevier in Cancer Letters
- Vol. 547, 215867
FGFR1/MAPK-directed brachyury activation drives PD-L1-mediated immune evasion to promote lung cancer progression
- Open Access
- 24 December 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (52) , 87124-87135
Regulation of brachyury by fibroblast growth factor receptor 1 in lung cancer
Regulation of brachyury by fibroblast growth factor receptor 1 in lung cancer
- 24 December 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (52) , 87124-87135
Open AccessRegulation of brachyury by fibroblast growth factor receptor 1 in lung cancer
Regulation of brachyury by fibroblast growth factor receptor 1 in lung cancer